

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Nakada, <i>et al.</i>	21 March 2007
Appln. No.	:	10/808699	Group Art Unit: 1644
Filed	:	24 March 2004	Examiner: Maher M. Haddad
Title	:	Use of Emmprin Antagonists for the Treatment of Diseases Associated with Excessive Angiogenesis	

Honorable Commissioner of Patents
Washington, D.C. 20231

AMENDMENT AFTER FINAL REJECTION

Dear Sir:

This is in response to the OFFICE ACTION mailed November 17, 2006, in the above referenced application. As this reply is being filed after the three-month response period, Applicants hereby petition Commissioner for a two month extension of time. Fees for the requested extension are being paid online via the Patent Office Electronic Filing System (EFS). The Commissioner is authorized to charge any additional fees related to the filing of this paper to Deposit Account 10-0750/CEN5017 USNP/KJD.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.